Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Rhea-AI Summary
Indivior (Nasdaq: INDV) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026 at 7:00 a.m. U.S. EST, followed by a live webcast presentation at 8:00 a.m. U.S. EST led by CEO Joe Ciaffoni and the leadership team.
Webcast access, registration details, and a replay will be available in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, INDV gained 0.55%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INDV gained 3.45% while peers were mixed: HCM -1.61%, AMRX +2.14%, BHC -1.80%, SUPN +0.67%, KNSA +3.19%, indicating stock-specific strength rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Redomiciliation completed | Positive | +1.9% | Completion of move to U.S. domicile with new Delaware parent structure. |
| Jan 08 | 2026 guidance update | Positive | -1.1% | Issued detailed 2026 revenue, SUBLOCADE, OPEX and EBITDA guidance. |
| Dec 22 | Index inclusion | Positive | +3.5% | Added to S&P SmallCap 600 index, reinforcing U.S. small-cap profile. |
| Dec 17 | Clinical trial data | Positive | +1.6% | SUBLOCADE study showed rapid and sustained reductions in opioid use. |
| Nov 20 | DOJ matter concluded | Positive | -2.5% | Paid <b>$295M</b> from cash on hand to terminate DOJ resolution agreement. |
Recent news has mostly been positive in tone, but price reactions have been mixed, with three aligned moves and two divergences following constructive corporate developments.
Over the past few months, Indivior has focused on U.S. capital markets positioning and operational clarity. It concluded a legacy DOJ matter with a $295M cash payment on Nov 20, 2025, gained inclusion in the S&P SmallCap 600 on Dec 22, 2025, and reported positive SUBLOCADE clinical data on Dec 17, 2025. In early 2026, it issued detailed 2026 financial guidance and completed redomiciliation to a new Delaware parent on Jan 26, 2026. The current earnings-date announcement fits into this structured communication cadence.
Market Pulse Summary
This announcement sets the timetable for Indivior’s fourth quarter and full-year 2025 results, with a release at 7:00 a.m. EST and a webcast at 8:00 a.m. EST. In recent months, the company has concluded a $295M DOJ obligation, joined the S&P SmallCap 600, issued detailed 2026 guidance, and completed U.S. redomiciliation. Investors may focus on how reported 2025 numbers align with that guidance, SUBLOCADE growth trends, and the company’s post-redomiciliation financial disclosures.
AI-generated analysis. Not financial advice.
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST.
Access to the Live Webcast Presentation:
The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.
Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat
Participants may access the presentation telephonically by registering with the following link:
https://register-conf.media-server.com/register/BI44fe43e28e334eb58b41edf49f6f80ce
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
A replay of the presentation will be available at www.indivior.com.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit https://www.indivior.com/ to learn more. Connect with Indivior on LinkedIn by visiting https://www.linkedin.com/company/indivior.
For Further Information
Investors:
Jason Thompson
Indivior PLC
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com
Media:
Cassie France-Kelly
Indivior PLC
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com
FAQ
When will Indivior (INDV) report fourth quarter and full-year 2025 results?
How can investors access the Indivior (INDV) February 26, 2026 webcast?
Who will present at Indivior (INDV) post-results webcast on February 26, 2026?
Is there a telephone option to join the Indivior (INDV) February 26, 2026 presentation?
Will a replay of the Indivior (INDV) February 26, 2026 webcast be available?
